Pocket Democracy

Jim Cramer says the bull market's remarkable 4-year run offers a crucial lesson for investors Four years ago this week, the S&P 500 closed at 3,577. The mood on trading floors was somewhere between shellshocked and resigned. Inflation was running hot, the Fed was about to embark on its most aggressive tightening cycle in decades, and the word "recession" was on everyone's lips. If you'd told an investor then that the index would be flirting with 7,800 by October 2026, a gain of roughly 118%, they might have asked what you were smoking. Jim Cramer certainly didn't see it coming. And that, he says, is precisely the point. "The real lesson is that there never seems to be a good time to invest, because bad things do happen quite regularly, and yet investing is a superior way to get a return," the "Mad Money" host said Monday, marking the bull market's fourth anniversary. It's the kind of line that sounds almost too simple, the sor...

Individual Investors Are Trading at Meme-Stock Levels I still remember the exact moment I realized the market had lost its mind again. It was a Tuesday morning in late April, and I was staring at a chart of Allbirds, a shoemaker that had never turned a profit, a company whose stock had spent most of its public life trading below ten dollars. In a single session, it had rocketed from roughly $2.50 to nearly $24. Not because of a breakthrough in sustainable footwear. Because it had slapped the letters "AI" onto its name and announced a pivot to compute infrastructure. The stock has since given most of that back, trading closer to $8 as of late April. But the damage to my sense of market normality was already done. This wasn't 2021. There were no stimulus checks. No pandemic lockdowns. No zero-interest-rate fever dreams. And yet here we were, watching the same playbook unfold in real time. So I started digging. What I found suggests that individual investors haven't just...

  Frenzied Stock-Options Trading Shows Individual Investors Are Still Hungry for Risk I remember the exact moment I realized something had fundamentally shifted in the market. It was a Tuesday afternoon in early 2026, and I was watching a friend, a 28-year-old graphic designer with zero formal finance training, explain the mechanics of a gamma squeeze with the kind of confidence usually reserved for people who actually work on trading floors. She'd made $14,000 that morning on a single options trade. She'd also lost $9,000 the week before. But you know what? She wasn't rattled. She was hungry. That conversation stuck with me. Because it wasn't about luck or recklessness, at least not entirely. It was about a generation of investors who've decided that the traditional path to building wealth is too slow, too boring, and frankly, too rigged against them. And the data backs that up in ways that should make anyone paying attention sit up straight. Trading in single-stoc...

  The Line That Could Pop the AI Bubble Ray Dalio said something in Singapore last week that stopped me cold. “Everybody says ‘I’m worth a billion dollars’ but OK, try to spend that,” the Bridgewater founder told the Forbes Global CEO Conference. “In order to spend that you have to sell wealth in order to get money, and so the bubble usually pricks at that”. He wasn’t talking about some abstract economic theory. He was describing the exact moment a bubble stops being a story about paper gains and becomes a story about cash. And right now, the AI boom is sprinting toward that moment with a borrowed credit card in one hand and a spreadsheet in the other. Here’s the thing nobody wants to say out loud: the line that pops this bubble isn’t a technology failure. It’s a financing failure. A simple, boring, brutal math problem. And the numbers are getting ugly. When capex eats your entire paycheck Let me put this in terms you can feel in your gut. UBS crunched the numbers and found that h...

  The $38 Trillion Question: Why the Smartest Money Is Betting on Cancer and Aging as One Problem A few months ago, I watched a hedge fund manager, someone who’d spent two decades pricing risk in biotech, lean back in his chair and say something that stopped the conversation cold. “We’ve been investing in cancer like it’s a hundred different diseases,” he said. “What if it’s just one disease, and that disease is aging?” He wasn’t trying to be provocative. He was reading the data. And the data, increasingly, points in exactly that direction. That’s the idea behind the blunt claim you may have seen circulating: “This is how we solve cancer, this is how we solve aging.” It sounds like a bumper sticker. It’s actually an investment thesis. And for anyone managing capital in 2026, understanding why those two problems are the same problem, and what that means for valuations, timelines, and risk, is no longer optional reading. It’s the difference between owning the next decade’s most i...